
Thursday, September 14, 2023 8:14:11 AM
Recent AMRN News
- New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline • GlobeNewswire Inc. • 11/12/2023 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 08:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/01/2023 11:05:43 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/01/2023 11:05:30 AM
- Amarin Reports Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 11/01/2023 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2023 08:05:30 PM
- Amarin Appoints Jonathan Provoost Executive Vice President, Chief Legal & Compliance Officer • GlobeNewswire Inc. • 10/31/2023 04:00:00 PM
- Latest Research Evaluating VASCEPA®/VAZKEPA® (icosapent ethyl) and Subgroups from the REDUCE-IT Landmark Outcomes Trial to be Presented at the American Heart Association (AHA) Scientific Sessions 2023 • GlobeNewswire Inc. • 10/26/2023 12:00:00 PM
- Amarin to Report Third Quarter 2023 Financial Results and Host Conference Call on November 1, 2023 • GlobeNewswire Inc. • 10/19/2023 12:00:00 PM
- Amarin to Present at the 2023 Cantor Global Healthcare Conference • GlobeNewswire Inc. • 09/12/2023 12:00:00 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 09/05/2023 08:15:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/16/2023 11:51:59 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/16/2023 04:15:24 AM
- Amarin Provides Pricing & Reimbursement Updates for VAZKEPA (icosapent ethyl) in The Netherlands and Italy • GlobeNewswire Inc. • 08/09/2023 08:05:00 PM
- Amarin And Neopharm Announce Exclusive Commercialization Agreement for VAZKEPA® (Icosapent Ethyl) in Israel • GlobeNewswire Inc. • 08/08/2023 11:00:00 AM
- Scottish Medicines Consortium Accepts VAZKEPA® (icosapent ethyl) to Help Reduce Cardiovascular Risk for Patients in Scotland(1) • GlobeNewswire Inc. • 08/07/2023 11:00:40 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/02/2023 09:06:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/02/2023 09:01:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/02/2023 09:00:33 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/02/2023 12:39:29 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 08/02/2023 12:34:32 PM
- Amarin Reports Second Quarter 2023 Financial Results • GlobeNewswire Inc. • 08/02/2023 11:11:03 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/02/2023 11:06:43 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2023 11:01:05 AM
- Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea • GlobeNewswire Inc. • 07/31/2023 12:00:00 PM
CGrowth Capital Inc. Sets Stage for Exciting 2024 with Savage Barbell Apparel Expansion • CGRA • Nov 28, 2023 11:15 AM
Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing • IMMX • Nov 28, 2023 10:48 AM
Swifty Global Secures GLI Certification for New Cutting-Edge B2B Gaming Platform • DRCR • Nov 28, 2023 9:15 AM
Nate's Food Co. Successfully Obtains GACC Registration in China, Paving the Way for Contract Execution on Commodities • NHMD • Nov 28, 2023 8:00 AM
Mass Megawatts Announces LOWEST PRICE GUARANTEE on Solar Project Sales and Further Cost Reductions Using our Patent Pending Technologies • MMMW • Nov 28, 2023 8:00 AM
Branded Legacy Commences Buyback of 1,000,000 Preferred Class D Shares • BLEG • Nov 28, 2023 7:23 AM